Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Helivax Antex Biologics.

G D Giudice1

  • 1IRIS Research Center, Chiron SpA, Siena, Italy. giuseppe_del_giudice@chiron.it

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary

An oral vaccine for Helicobacter pylori infection shows promise for treating and preventing gastric ulcers. The vaccine was well-tolerated and generated an immune response in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvants LT-K63 and CpG enhance the activation of dendritic cells in neonatal mice.

Scandinavian journal of immunology·2008
Same author

Effects of LT-K63 and CpG2006 on phenotype and function of murine neonatal lymphoid cells.

Scandinavian journal of immunology·2007
See all related articles

Area of Science:

  • Gastroenterology
  • Vaccinology
  • Infectious Diseases

Background:

  • Helicobacter pylori infection is a major cause of gastric ulcers.
  • Current treatments can be limited by antibiotic resistance and side effects.
  • There is a need for effective prophylactic and therapeutic strategies against H. pylori.

Purpose of the Study:

  • To evaluate the safety and immunogenicity of an oral vaccine against H. pylori.
  • To assess the vaccine's potential for treating and preventing gastric ulcers.

Main Methods:

  • A two-part phase Ib/II clinical trial was conducted.
  • Part one involved an open-label safety assessment in infected and uninfected individuals.
  • Part two was an expanded placebo-controlled study evaluating safety and immunogenicity.

Main Results:

  • The oral H. pylori vaccine was generally well-tolerated.
  • The vaccine successfully generated an immune response in both infected and non-infected participants.
  • Phase II trial enrollment was completed in September 2000.

Conclusions:

  • The oral H. pylori vaccine demonstrates a favorable safety profile.
  • The vaccine is immunogenic and shows potential as a therapeutic and prophylactic agent for H. pylori infection and gastric ulcers.

Related Experiment Videos